Company Overview and News
QuinStreet (QNST - Free Report) is a Zacks Rank #1 (Strong Buy) and sports a growth style score of A. That alone gets the stock on my radar screen but lately, I have been looking hunting some bears. By that, I mean I am looking for stocks that have big short positions or at least have been attacked by the shorts.
ENSG UCTI APR APRLY QNST UCTT
It’s undeniable that the U.S. population is aging. This demographic shift will accelerate as increasing numbers of baby-boomers – those born between 1946 and 1964 – reach retirement age. The number of Americans aged 65 and older is projected to more than double from 46 million to over 95 million by 2060 when this age group will be approximately 25% of the population.
SIX ENSG UCTI UCTT
MKS Instruments, Inc. (MKSI - Free Report) , in our opinion, is a solid choice for investors seeking exposure in the electronics space. The stock, with roughly $5.6-billion market capitalization, was upgraded to a Zacks Rank #1 (Strong Buy) on Jun 13. Its investment appeal is further accentuated by a VGM Score of A. MKS Instruments posted better-than-expected results in three of the last four quarters, while reporting in-line earnings in one, delivering an average positive earnings surprise of 4.
MKSI UCTI VECO ACLS UCTT
Have you been paying attention to shares of Entegris (ENTG - Free Report) ? Shares have been on the move with the stock up 8.4% over the past month. ENTG hit a new 52-week high of $39.10 in the previous session. Entegris has gained 27.6% since the start of the year compared to the 9.5% move for the Computer and Technology sector and the 12.7% year-to-date return for its peer group.
ENTG KMG MKSI UCTI ACLS UCTT RCKY
Tech stocks have been on a tear this year and Wednesday’s session was no exception with the Nasdaq closing 0.5% higher. Overall, tech stocks have been largely responsible for the long-running market rally. But bubble fears are making a comeback courtesy of a bunch of leading analysts and market watchers.
BAC WDC STX UCTI UTX BAC IMMR ALIMR AMZN MU AAPL MSFT NANO UCTT
Investors with an interest in Electronics - Manufacturing Machinery stocks have likely encountered both Ultra Clean Holdings (UCTT - Free Report) and Cohu (COHU - Free Report) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.
BRQS MU UCTI LB COHU UCTT
Here at Zacks, we don’t generally classify stocks as “cheap” or “expensive”, and rather than looking at the stock’s face value, we have a system that puts an emphasis on earnings estimate revisions to find stocks that will hopefully be winners for investors.
CVGI TRCB AUDC CY CFCO CFCOW UCTI CFCOU BB BB TLRD UCTT
uctt-10k_20171229.htm UNITED STATES
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
2018-06-11 - Asif
Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...
2018-06-11 - Asif
Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...
as of ET